NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD
Taking everything into account, FATE scores 3 out of 10 in our fundamental rating. FATE was compared to 556 industry peers in the Biotechnology industry. FATE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FATE is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -44.12% | ||
ROE | -60.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.11 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.81 | ||
Quick Ratio | 8.81 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:FATE (7/23/2025, 12:54:54 PM)
1.285
+0.04 (+3.63%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 11.05 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.51 | ||
P/tB | 0.51 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -44.12% | ||
ROE | -60.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 10.53% | ||
Cap/Sales | 13.8% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.81 | ||
Quick Ratio | 8.81 | ||
Altman-Z | -5.11 |